Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson’s disease mutant of Leucine-rich repeat kinase 2 (LRRK2)

被引：0
|
作者：
Radek Linhart
Sarah Anne Wong
Jieyun Cao
Melody Tran
Anne Huynh
Casey Ardrey
Jong Min Park
Christine Hsu
Saher Taha
Rentia Peterson
Shannon Shea
Jason Kurian
Katerina Venderova
机构：
[1] University of the Pacific,Department of Physiology and Pharmacology, Thomas J. Long School of Pharmacy and Health Sciences
来源：
Molecular Neurodegeneration | / 9卷
关键词：
Parkinson’s disease; LRRK2; VPS35; Retromer; Endolysosomal pathway; Drosophila; Genetics; Rotenone; Neurodegeneration; Endosomes; Lysosome; VPS26;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A meta-analysis of leucine-rich repeat kinase 2 (LRRK2) polymorphisms in Alzheimer's disease
    Fatahian, Reza
    Bagheri, Seyed Reza
    Sadeghi, Masoud
    FOLIA NEUROPATHOLOGICA, 2019, 57 (01) : 1 - 5
  • [32] Hypothesis: Do miRNAs Targeting the Leucine-Rich Repeat Kinase 2 Gene (LRRK2) Influence Parkinson's Disease Susceptibility?
    Yilmaz, Senay Gorucu
    Geyik, Sirma
    Neyal, Ayse Munife
    Soko, Nyarai D.
    Bozkurt, Hakan
    Dandara, Collet
    OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2016, 20 (04) : 224 - 228
  • [33] The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play
    Azeggagh, Sonia
    Berwick, Daniel C.
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (08) : 1478 - 1495
  • [34] Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease
    Patel, Ashish
    Patel, Stuti
    Mehta, Meshwa
    Patel, Yug
    Langaliya, Dhruv
    Bhalodiya, Shyam
    Bambharoliya, Tushar
    MEDICINAL CHEMISTRY, 2022, 18 (07) : 757 - 771
  • [35] Dyskinesias in patients with Parkinson's disease: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation
    Yahalom, Gilad
    Kaplan, Natalie
    Vituri, Aya
    Cohen, Oren S.
    Inzelberg, Rivka
    Kozlova, Evgenia
    Korczyn, Amos D.
    Rosset, Saharon
    Friedman, Eitan
    Hassin-Baer, Sharon
    PARKINSONISM & RELATED DISORDERS, 2012, 18 (09) : 1039 - 1041
  • [36] Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil
    Abreu, Gabriella de M.
    Valenca, Debora Cristina T.
    Campos Junior, Mario
    da Silva, Camilla P.
    Pereira, Joao S.
    Araujo Leite, Marco A.
    Rosso, Ana Lucia
    Nicaretta, Denise H.
    Vasconcellos, Luiz Felipe R.
    da Silva, Delson Jose
    Della Coletta, Marcus V.
    dos Santos, Jussara M.
    Goncalves, Andressa P.
    Santos-Reboucas, Cintia B.
    Pimentel, Marcia M. G.
    NEUROSCIENCE LETTERS, 2016, 635 : 67 - 70
  • [37] Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2)
    Beylina, Aleksandra
    Langston, Rebekah G.
    Rosen, Dorien
    Reed, Xylena
    Cookson, Mark R.
    STEM CELL RESEARCH, 2021, 53
  • [38] Analysis of Leucine-rich repeat kinase 2 (LRRK2) and Parkinson protein 2 (parkin, PARK2) genes mutations in Slovak Parkinson disease patients
    Bognar, Csaba
    Baldovic, Marian
    Benetin, Jan
    Kadasi, Ludovit
    Zatkova, Andrea
    GENERAL PHYSIOLOGY AND BIOPHYSICS, 2013, 32 (01) : 55 - 66
  • [39] Rac1 Protein Rescues Neurite Retraction Caused by G2019S Leucine-rich Repeat Kinase 2 (LRRK2)
    Chan, Diane
    Citro, Allison
    Cordy, Joanna M.
    Shen, Grace C.
    Wolozin, Benjamin
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (18) : 16140 - 16149
  • [40] Targeting leucine-rich repeat kinase 2 in Parkinson's disease
    Chan, Sharon L.
    Angeles, Dario C.
    Tan, Eng-King
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (12) : 1471 - 1482
12345